Rainvis Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 1.50 M
- Company Age 14 Year, 7 Months
- Last Filing with ROC 31 Mar 2019
- Open Charges ₹ 2.50 M
- Revenue Growth -3.80%
- Profit Growth 64.83%
- Ebitda 65.43%
- Net Worth -49.21%
- Total Assets -12.90%
About Rainvis Pharmaceuticals
Rainvis Pharmaceuticals Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 July 2010 and has a history of 14 years and seven months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company currently has active open charges totaling ₹2.50 M.
Ranjit Parija and Parul Rautray serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24239GJ2010PTC061454
-
Company No.
061454
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
06 Jul 2010
-
Date of AGM
30 Sep 2019
-
Date of Balance Sheet
31 Mar 2019
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Rainvis Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ranjit Parija
|
Director | 22-Jan-2019 | Current |
|
Parul Rautray
|
Director | 23-Feb-2017 | Current |
Financial Performance of Rainvis Pharmaceuticals.
Rainvis Pharmaceuticals Private Limited, for the financial year ended 2019, experienced Minor drop in revenue, with a 3.8% decrease. The company also saw a substantial improvement in profitability, with a 64.83% increase in profit. The company's net worth observed a substantial decline by a decrease of 49.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rainvis Pharmaceuticals?
In 2019, Rainvis Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹2.50 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.25 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Dec 2017 | Others | ₹2.50 M | Open |
How Many Employees Work at Rainvis Pharmaceuticals?
Unlock and access historical data on people associated with Rainvis Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rainvis Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rainvis Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
